Zim Biosciences, Inc. is a startup biopharmaceutical company whose mission is to change the treatment paradigm for skin care. Our technology combines the power of advanced polymer science and protein chemistry to induce a patient’s own biological system to start the healing process by creating an instant natural skin barrier and a scaffold for cellular repair. This instant skin barrier allows for faster healing, shortened recovery time, and a decrease in infection and scarring. We are committed… Show more Zim Biosciences, Inc. is a startup biopharmaceutical company whose mission is to change the treatment paradigm for skin care. Our technology combines the power of advanced polymer science and protein chemistry to induce a patient’s own biological system to start the healing process by creating an instant natural skin barrier and a scaffold for cellular repair. This instant skin barrier allows for faster healing, shortened recovery time, and a decrease in infection and scarring. We are committed to pioneering and developing leading-edge biotherapies that address the unmet medical need for wound healing, which will vastly improve patients’ lives. Zim Biosciences, Inc. has a patent-pending large molecule complex that has already been commercialized on the consumer market. This complex has demonstrated significantly faster healing and less scarring on damaged skin. We believe our product will be highly valued by skin and wound care patients in a large range of markets, from household consumers to critical care and military. Better simple solutions and products will add true value to a patient's health management.The demand for advanced wound care products is expected to rise over the next 10 years, driven by growths in an aging population and an increase in lifestyle related disorders such as diabetes and obesity. Our product is anticipated to address multiple unmet medical needs including: (1) improving skin integrity; (2) preventing wound infection; (3) preventing and managing scars; (4) speeding the generation of a viable wound bed; and (5) preventing burn inflammation and injury progression. Our long-term strategy is to advance surgical wound healing and battlefield care with our products. http://zimbiosciences.com Show less

Almost 10 years ago I co-founded Rx3 with 5 bold scientists and a dynamic CFO. We started and finished in a way not many biotech's in town can claim fame to. As the company grew, in 2007 we gained a visionary CEO who in licensed a molecule, and led the company all the way to a big pharma buyout . As of today (2014), I will be looking for a new (ad)venture! Stay tuned for Chapter 2!

Significant Achievements:• Co-founder and first employee of the company.• Established a pre-clinical Microbiology department and assays for determining activity of novel compounds. Established pre-clinical Pharmacology department.• Program manager for lead project including 1st- demonstration of in vivo activity for a new class of antibiotics.

Significant Achievements:• Demonstrated proof of concept for the depletion of cellular mRNA due to induction of antisense RNA plasmids in S. aureus. • Instrumental in developing novel assays for detection of antisense target validation screening in bacteria for new antibiotics.• Validated mechanism of action for 74 promoter replacement over-expression S. aureus strains.

Significant Achievements:• Designed, developed and executed an innovative new assay, Antisense Target Validation technology (ATV), to rapidly determine the pharmacological impact of inhibiting the expression of gene targets. Re-named GeneTrove, the objective was to generate high-quality gene functionalization and target validation information to facilitate the discovery and development of new drugs.• Discovered the mechanism of action for Vitravene, a drug used to treat CMV retinitis… Show more Significant Achievements:• Designed, developed and executed an innovative new assay, Antisense Target Validation technology (ATV), to rapidly determine the pharmacological impact of inhibiting the expression of gene targets. Re-named GeneTrove, the objective was to generate high-quality gene functionalization and target validation information to facilitate the discovery and development of new drugs.• Discovered the mechanism of action for Vitravene, a drug used to treat CMV retinitis. New Drug Application (NDA) was filed and approved by the FDA in 1998. Vitravene was first antisense drug to market.• Developed a Hepatitis C Virus (HCV)/hepatocyte transfer assay in mice for antiviral drug testing. Show less

Molecular biology projects in malaria.